

Figure 1A

Demographic	ASLAN004 200mg (N = 5)	ASLAN004 400mg (N = 8)	ASLAN004 600mg (N = 5)	Placebo (N = 7)	Total (N = 25)
Age (yrs)					
Mean (SD)	30.4 (6.5)	29.4 (4.5)	46.6 (17.5)	33.6 (14.4)	34.2 (12.6)
Min, Max	22, 38	23, 36	25, 68	22, 61	22, 68
Sex					
Male	3 (60.0%)	6 (75.0%)	3 (60.0%)	5 (71.4%)	17 (68.0%)
Female	2 (40.0%)	2 (25.0%)	2 (40.0%)	2 (28.6%)	8 (32.0%)
Race					
Asian	5 (100%)	8 (100%)	2 (40.0%)	7 (100%)	22 (88.0%)
Black	0	0	1 (20.0%)	0	1 (4.0%)
White	0	0	2 (40.0%)	0	2 (8.0%)
Ethnicity					
Not Hispanic or Latino	5 (100%)	8 (100%)	5 (100%)	7 (100%)	25 (100%)
Height (cm)					
Mean (SD)	169.8 (5.7)	169.0 (5.6)	164.9 (12.5)	170.6 (8.1)	168.8 (7.8)
Min, Max	161.0, 175.0	160.7, 177.2	150.0, 182.0	159.2, 182.4	150.0, 182.4
Weight (kg)					
Mean (SD)	73.3 (12.3)	73.9 (14.0)	71.4 (21.0)	70.0 (15.1)	72.2 (14.7)
Min, Max	58.4, 90.5	53.8, 88.7	45.0, 92.0	53.7, 97.2	45.0, 97.2
BMI (kg/m²)					
Mean (SD)	25.3 (2.8)	25.9 (5.0)	26.6 (8.8)	24.3 (6.6)	25.5 (5.8)
Min, Max	22.5, 29.6	18.4, 32.8	16.9, 37.1	17.8, 38.4	16.9, 38.4

Figure 1B

Demographic		ASLAN004 200mg (N = 5)		ASLAN004 400mg (N = 8)		ASLAN004 600mg (N = 5)		Placebo (N = 7)		Total (N = 25)	
EASI	Mean (SD)	29.6 (14.4)		30.5 (11.6)		29.0 (11.8)		30.4 (10.3)		30.0 (11.1)	
	Min, Max	16.6, 52.5		18.6, 48.6		22.0, 50.0		16.2, 42.0		16.2, 52.5	
IGA	3	3 (60.0%)		6 (75.0%)		3 (60.0%)		4 (57.1%)		16 (64.0)	
	4	2 (40.0%)		2 (25.0%)		2 (40.0%)		3 (42.9%)		9 (36.0)	
Pruritus Numerical Rating Scale (7-Day Average Scores)											
Average Itching	N	5		8		3		7		23	
	Mean (SD)	6.6 (1.6)		6.7 (1.5)		5.5 (1.0)		6.5 (2.1)		6.5 (1.6)	
	Min, Max	4.7, 8.6		3.7, 8.5		4.8, 6.7		4.3, 9.3		3.7, 9.3	
Worse Itching	N	5		8		3		7		23	
	Mean (SD)	7.4 (1.9)		7.8 (1.4)		7.1 (1.2)		7.3 (2.2)		7.5 (1.7)	
	Min, Max	4.6, 9.7		5.3, 10.0		6.3, 8.4		4.3, 10.0		4.3, 10.0	

Figure 1C

Demographic	ASLAN004				Total (N = 18)
	200mg (N = 4)	400mg (N = 6)	600mg (N = 3)	Placebo (N = 5)	
EASI	Mean (SD)	32.9 (14.3)	30.9 (13.4)	32.5 (15.2)	32.5 (11.8)
	Min, Max	18.3, 52.5	18.6, 48.6	22.6, 50.0	18.3, 52.5
IGA	3	2 (50.0%)	5 (83.3%)	1 (33.3%)	10 (55.6)
	4	2 (50.0%)	1 (16.7%)	2 (66.7%)	8 (44.4)
Pruritus Numerical Rating Scale (7-Day Average Scores)					
Average Itching	N	4	6	2	17
	Mean (SD)	7.0 (1.7)	6.3 (1.5)	4.9 (0.3)	6.4 (1.7)
	Min, Max	4.7, 8.6	3.7, 7.9	4.8, 5.1	3.7, 9.3
Worse Itching	N	4	6	2	17
	Mean (SD)	7.4 (2.2)	7.3 (1.3)	6.4 (0.2)	7.2 (1.7)
	Min, Max	4.6, 9.7	5.3, 9.1	6.3, 6.5	4.3, 10.0

Figure 2A

Treatment Arm	N	Mean	Diff (vs. Placebo)
Placebo	5	-42.4%	-
ASLAN004 200 mg QW	4	-49.5%	-7.1%
ASLAN004 400 mg QW	6	-73.6%	-31.2%
ASLAN004 600 mg QW	3	-75.8%	-33.4%
<i>ASLAN004 High Doses</i>	<i>9</i>	<i>-74.3%</i>	<i>-31.9%</i>

Figure 2B




Figure 2C




Figure 3A

Treatment Arm	N	Mean	Diff (vs. Placebo)
Placebo	5	-30.5%	-
ASLAN004 200 mg	4	-51.2%	-20.7%
ASLAN004 400 mg	6	-63.7%	-33.2%
ASLAN004 600 mg	3	-53.6%	-23.1%
ASLAN004 High Doses	9	-60.4%	-29.8%

Figure 3B





Figure 4A






Figure 4B

Figure 5A




Figure 5B - % Change from baseline in EASI score over time: EES (ASLAN004 200mg)




Figure 5C




Figure 5D





Figure 6A

Analysis Set	Treatment Arm	N	Mean	Diff (vs. Placebo)
EES (Primary)	Placebo	5	-42.9%	-
	ASLAN004 200 mg	4	-49.5%	-7.1%
	ASLAN004 400 mg	6	-73.6%	-31.2%
	ASLAN004 600 mg	3	-75.8%	-33.4%
mITT (sensitivity)	Placebo	6	-31.4%	
	ASLAN004 200mg	4	-49.5%	-18.9%
	ASLAN004 400mg	7	-63.1%	-31.6%
	ASLAN004 600mg	5	-47.1%	-15.7%

Figure 6B






Figure 6C

Figure 7A

Treatment Group	EASI 50 N (%)	EASI 75 N (%)	EASI 90 N (%)
Placebo (n=5)	2 (40.0%)	0	0
ASLAN004 200mg (n=4)	2 (50.0%)	2 (50.0%)	0
ASLAN004 400mg (n=6)	5 (83.3%)	4 (66.7%)	4 (66.7%)
ASLAN004 600mg (n=3)	3 (100%)	2 (66.7%)	1 (33.3%)
ASLAN004 High Doses (n=9)	8 (88.9%)	6 (66.7%)	5 (55.6%)

Figure 7B




Figure 7C




Figure 7D




Figure 7E




Figure 7F





Figure 7G






Figure 8A




Figure 8B




Figure 8C


Figure 9

Analysis Set	Treatment Arm	EASI 50	EASI 75	EASI 90
EES (Primary)	Placebo (n=5)	2 (40.0%)	0	0
	ASLAN004 200 mg (n=4)	2 (50.0%)	2 (50.0%)	0
	ASLAN004 400 mg (n=6)	5 (83.3%)	4 (66.7%)	4 (66.7%)
	ASLAN004 600 mg (n=3)	3 (100%)	2 (66.7%)	1 (33.3%)
	<i>ASLAN004 High Doses (n=9)</i>	<i>8 (88.9%)</i>	<i>6 (66.7%)</i>	<i>5 (55.6%)</i>
mITT (sensitivity)	Placebo (n=6)	2 (33.3%)	0	0
	ASLAN004 200mg (n=4)	2 (50.0%)	2 (50.0%)	0
	ASLAN004 400mg (n=7)	5 (71.4%)	4 (57.1%)	4 (57.1%)
	ASLAN004 600mg (n=5)	4 (80.0%)	2 (40.0%)	1 (20.0%)
	<i>ASLAN004 High Doses (n=12)</i>	<i>8 (66.7%)</i>	<i>6 (50%)</i>	<i>5 (41.7%)</i>

Figure 10A

Treatment Group	IGA 0/1 N (%)
Placebo (n=5)	0
ASLAN004 200mg (n=4)	0
ASLAN004 400mg (n=6)	1 (16.7%)
ASLAN004 600mg (n=3)	1 (33%)
ASLAN004 High Doses (n=9)	2 (22.2%)

Figure 10B






Figure 10C

Figure 11

Study	TARC pg/mL	IgE (kU/L)
ASLAN004 200 mg QW N=4	6097.1 ± 3123.4	14993.1 ± 6567.8
ASLAN004 400mg QW N=6	2699.6 ± 979.7	13521.7 ± 5362.5
ASLAN004 Placebo N=3	6488.5 ± 4572.8	12790.1 ± 7902.4
Dupilumab Ph2a 300 mg QW N=55	4013 ± 577.7	7179.6 ± 1419.6
Dupilumab Ph2a Placebo N=54	5665.8 ± 1449.1	7293.8 ± 1158.2

Figure 12A





Figure 12B






Figure 12C

Figure 13A




Figure 13B




Figure 13C




Figure 13D




Figure 13E




Figure 14




Figure 15

Study	Av %cfbl EASI Day 57	% Patients at Day 57 (or as stated for Dupilumab)		
		EASI 75	EASI 90	IGA0/1
ASLAN004 400mg QW (N=6)	-73.6	66.7	66.7	16.7
ASLAN004 400 & 600mg QW (N=9)	-74.3	66.7	55.6	22.2
ASLAN004 placebo (N=5)	-42.4	0	0	0
Dupilumab Ph2a 300mg QW (N=55)	-75%	62 ^a	Not reported	35
Dupilumab Ph 2a placebo (N=54)	-20%	15 ^a	Not reported	3
Dupilumab Ph2b 300mg QW (N=63)	-68%	50	20	33 ^b
Dupilumab Ph2b placebo (N=61)	-15%	10	5	2 ^b
Dupilumab Ph3 300mg QW (N=456)*	-65%	50 ^b	32 ^b	37 ^b
Dupilumab Ph3 placebo (N=460)	-25%	14 ^b	8 ^b	9 ^b